Unknown

Dataset Information

0

Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.


ABSTRACT: PURPOSE:Identification of serum biomarkers enabling earlier diagnosis of pancreatic ductal adenocarcinoma (PDAC) could improve outcome. Serum protein profiles in patients with preclinical disease and at diagnosis were investigated. EXPERIMENTAL DESIGN:Serum from cases up to 4 years prior to PDAC diagnosis and controls (UKCTOCS,n= 174) were studied, alongside samples from patients diagnosed with PDAC, chronic pancreatitis, benign biliary disease, type 2 diabetes mellitus, and healthy subjects (n= 298). Isobaric tags for relative and absolute quantification (iTRAQ) enabled comparisons of pooled serum from a test set (n= 150). Validation was undertaken using multiple reaction monitoring (MRM) and/or Western blotting in all 472 human samples and samples from a KPC mouse model. RESULTS:iTRAQ identified thrombospondin-1 (TSP-1) as reduced preclinically and in diagnosed samples. MRM confirmed significant reduction in levels of TSP-1 up to 24 months prior to diagnosis. A combination of TSP-1 and CA19-9 gave an AUC of 0.86, significantly outperforming both markers alone (0.69 and 0.77, respectively;P< 0.01). TSP-1 was also decreased in PDAC patients compared with healthy controls (P< 0.05) and patients with benign biliary obstruction (P< 0.01). Low levels of TSP-1 correlated with poorer survival, preclinically (P< 0.05) and at clinical diagnosis (P< 0.02). In PDAC patients, reduced TSP-1 levels were more frequently observed in those with confirmed diabetes mellitus (P< 0.01). Significantly lower levels were also observed in PDAC patients with diabetes compared with individuals with type 2 diabetes mellitus (P= 0.01). CONCLUSIONS:Circulating TSP-1 levels decrease up to 24 months prior to diagnosis of PDAC and significantly enhance the diagnostic performance of CA19-9. The influence of diabetes mellitus on biomarker behavior should be considered in future studies.

SUBMITTER: Jenkinson C 

PROVIDER: S-EPMC4820087 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.

Jenkinson Claire C   Elliott Victoria L VL   Evans Anthony A   Oldfield Lucy L   Jenkins Rosalind E RE   O'Brien Darragh P DP   Apostolidou Sophia S   Gentry-Maharaj Aleksandra A   Fourkala Evangelia-O EO   Jacobs Ian J IJ   Menon Usha U   Cox Trevor T   Campbell Fiona F   Pereira Stephen P SP   Tuveson David A DA   Park B Kevin BK   Greenhalf William W   Sutton Robert R   Timms John F JF   Neoptolemos John P JP   Costello Eithne E  

Clinical cancer research : an official journal of the American Association for Cancer Research 20151116 7


<h4>Purpose</h4>Identification of serum biomarkers enabling earlier diagnosis of pancreatic ductal adenocarcinoma (PDAC) could improve outcome. Serum protein profiles in patients with preclinical disease and at diagnosis were investigated.<h4>Experimental design</h4>Serum from cases up to 4 years prior to PDAC diagnosis and controls (UKCTOCS,n= 174) were studied, alongside samples from patients diagnosed with PDAC, chronic pancreatitis, benign biliary disease, type 2 diabetes mellitus, and healt  ...[more]

Similar Datasets

| S-EPMC5751272 | biostudies-literature
| S-EPMC7292217 | biostudies-literature
| S-EPMC8884722 | biostudies-literature
| S-EPMC8664824 | biostudies-literature
| S-EPMC4723135 | biostudies-literature
| S-EPMC8575726 | biostudies-literature
| S-EPMC6972272 | biostudies-literature
| S-EPMC10147931 | biostudies-literature
| S-EPMC5864123 | biostudies-literature